Cg Oncology Inc (CGON)

$33.34 +0.18 (0.54%)
Market Cap 2.54B
Revenue (ttm) 1.14M
Net Income (ttm) -88.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,722.81%
Debt to Equity Ratio 0.00
Volume 1,398,900
Avg Vol 897,758
Day's Range N/A - N/A
Shares Out 76.25M
Stochastic %K 84%
Beta 0.87
Analysts Strong Sell
Price Target $56.00

Company Profile

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC p...

Industry: Biotechnology
Sector: Healthcare
Phone: 949 409 3700
Address:
400 Spectrum Center Drive, Suite 2040, Irvine, United States
stockinfocuz_
stockinfocuz_ Sep. 9 at 4:32 PM
$ONCY Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market $HCM $CGON $IDYA $CCCC https://barchart.com/share/news/34665959 via @Barchart
0 · Reply
Main_Street_Risks
Main_Street_Risks Sep. 9 at 1:56 AM
$CGON looking real good. Clearly giving institutional investors confidence with the recent talks. Short term, this is a little stretched for me though. But pivot-6 enrollment was a pleasant surprise. Might even see $45 on this run. Regardless I think this is probably a good multiyear hold from here
0 · Reply
JarvisFlow
JarvisFlow Sep. 8 at 4:26 PM
Jones Trading updates rating for CG Oncology ( $CGON ) to Buy, target set at 50.
0 · Reply
JarvisFlow
JarvisFlow Sep. 8 at 12:00 PM
HC Wainwright & Co. updates rating for CG Oncology ( $CGON ) to Buy, target set at 75.
0 · Reply
RiskCPremium
RiskCPremium Sep. 5 at 7:55 PM
$RLMD After the licensing agreement with Trigone for NDV-01 gel, stock price recovered a bit but still selling at an extremely deep Sergio Traversa/Key-Man/Conman discount. Just look at $CGON today, both are going after the same market but the NDV-01 gel shown much better efficacy so far. He burned and conned not only the shareholders but also analysts from reputable investment banks. That's why current stock price is $1.60 but analysts are keeping their average target price at $1.00. Dr. Raj Pruthi current CMO should lead the company. Trigone & Squadron Capital Management LLC should lead the Board.
1 · Reply
Grinding10
Grinding10 Sep. 5 at 3:22 PM
$CGON yeah ok there’s no insider trading I guess? $5 in 2 days when this hasn’t moved in 2 years
0 · Reply
MoneyWise13
MoneyWise13 Sep. 5 at 3:01 PM
$CGON This has BP buyout written all over it
1 · Reply
prismmarketview
prismmarketview Sep. 5 at 2:59 PM
(NASDAQ: $CGON) #cgoncology reports a 41.8% complete response rate at 24 months for cretostimogene in high-risk, BCG-unresponsive NMIBC. Impressively, 90% of 12-month responders remain disease-free at 24 months, with no serious treatment-related adverse events. https://prismmarketview.com/cg-oncologys-cretostimogene-sustains-durability-and-safety-12-new-patients-in-response-at-24-month/
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 4 at 10:00 PM
$CGON Excellent article that nails exactly where CGON stands right now. So if you want to update your CGON knowledge or get acquainted with CGON, this is a must read. https://beyondspx.com/quote/CGON/cg-oncology-unpacking-the-bladder-cancer-catalyst-cgon#analysis
0 · Reply
BullishBee
BullishBee Sep. 4 at 7:36 PM
🚀 Momentum Breakout Win: $CGON • Entry: $28.96 • Take Profit 1: $30.41 (+5.0%) • Final Exit: $31.60 (+9.1% Trail) • Return Locked: +7.1% (Total) Another premium breakout delivered with precision. Risk-free trade secured early, and the trailing stop locked in additional gains. The BullishBee momentum streak is alive and buzzing 🐝🔥
0 · Reply
Latest News on CGON
CG Oncology, Inc. (CGON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 9, 2025, 10:31 AM EDT - 5 days ago

CG Oncology, Inc. (CGON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

CG Oncology Stock Signals Bullish Momentum Ahead

Sep 8, 2025, 9:08 AM EDT - 6 days ago

CG Oncology Stock Signals Bullish Momentum Ahead

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

Sep 5, 2025, 7:00 AM EDT - 9 days ago

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

CG Oncology Completes Enrollment in PIVOT-006

Sep 3, 2025, 8:00 AM EDT - 11 days ago

CG Oncology Completes Enrollment in PIVOT-006

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 8, 2025, 8:00 AM EDT - 5 weeks ago

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)

Jun 23, 2025, 9:58 AM EDT - 2 months ago

CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 5, 2025, 8:00 AM EDT - 3 months ago

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

May 13, 2025, 8:00 AM EDT - 4 months ago

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why

Apr 28, 2025, 11:14 AM EDT - 4 months ago

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

Apr 26, 2025, 4:10 PM EDT - 5 months ago

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

CG Oncology Looks Attractive At Current Prices (Rating Upgrade)

Apr 2, 2025, 12:32 PM EDT - 5 months ago

CG Oncology Looks Attractive At Current Prices (Rating Upgrade)

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

Mar 24, 2025, 8:00 AM EDT - 6 months ago

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:00 AM EST - 7 months ago

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 16, 2024, 4:05 PM EST - 9 months ago

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene

Dec 13, 2024, 2:09 PM EST - 9 months ago

CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene

CG Oncology Announces Pricing of Public Offering

Dec 12, 2024, 8:19 PM EST - 9 months ago

CG Oncology Announces Pricing of Public Offering

CG Oncology Announces Proposed Public Offering

Dec 11, 2024, 6:17 AM EST - 9 months ago

CG Oncology Announces Proposed Public Offering

Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer

Dec 6, 2024, 1:18 PM EST - 10 months ago

Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Dec 6, 2024, 8:00 AM EST - 10 months ago

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Dec 5, 2024, 7:00 AM EST - 10 months ago

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 30, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

CG Oncology: Promising Data, But Looks Expensive

Aug 26, 2024, 10:34 AM EDT - 1 year ago

CG Oncology: Promising Data, But Looks Expensive

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 8, 2024, 8:23 AM EDT - 1 year ago

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

CG Oncology Bringing Undervalued Innovation To Bladder Cancer

Jul 9, 2024, 9:19 AM EDT - 1 year ago

CG Oncology Bringing Undervalued Innovation To Bladder Cancer

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

Jun 6, 2024, 12:14 PM EDT - 1 year ago

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

May 24, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

May 9, 2024, 8:00 AM EDT - 1 year ago

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value

May 6, 2024, 1:04 PM EDT - 1 year ago

CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

May 3, 2024, 11:23 AM EDT - 1 year ago

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

Apr 26, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

Apr 24, 2024, 10:00 AM EDT - 1 year ago

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

Mar 28, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

Protara: A Bombed Out Biotech With A Very Positive Skew

Feb 22, 2024, 8:55 AM EST - 1 year ago

Protara: A Bombed Out Biotech With A Very Positive Skew

TARA

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 30, 2024, 7:00 AM EST - 1 year ago

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

American Healthcare REIT, Fortegra and Fractyle Health set IPO price ranges as thaw continues

Jan 29, 2024, 8:14 AM EST - 1 year ago

American Healthcare REIT, Fortegra and Fractyle Health set IPO price ranges as thaw continues

BTSG

U.S. IPO Weekly Recap: Biotech CG Oncology Pops 96% In A 7 IPO Week

Jan 27, 2024, 1:30 AM EST - 1 year ago

U.S. IPO Weekly Recap: Biotech CG Oncology Pops 96% In A 7 IPO Week

Biotech's First IPO of 2024 Popped 96%. What It Means.

Jan 26, 2024, 11:50 AM EST - 1 year ago

Biotech's First IPO of 2024 Popped 96%. What It Means.

CG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionality

Jan 25, 2024, 2:20 PM EST - 1 year ago

CG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionality

CG Oncology valued at $1.75 bln in strong market debut

Jan 25, 2024, 1:46 PM EST - 1 year ago

CG Oncology valued at $1.75 bln in strong market debut

CG Oncology IPO prices above range and boosts share count in bullish move ahead of trading

Jan 25, 2024, 7:51 AM EST - 1 year ago

CG Oncology IPO prices above range and boosts share count in bullish move ahead of trading

CG Oncology Announces Pricing of Upsized Initial Public Offering

Jan 24, 2024, 7:10 PM EST - 1 year ago

CG Oncology Announces Pricing of Upsized Initial Public Offering

stockinfocuz_
stockinfocuz_ Sep. 9 at 4:32 PM
$ONCY Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market $HCM $CGON $IDYA $CCCC https://barchart.com/share/news/34665959 via @Barchart
0 · Reply
Main_Street_Risks
Main_Street_Risks Sep. 9 at 1:56 AM
$CGON looking real good. Clearly giving institutional investors confidence with the recent talks. Short term, this is a little stretched for me though. But pivot-6 enrollment was a pleasant surprise. Might even see $45 on this run. Regardless I think this is probably a good multiyear hold from here
0 · Reply
JarvisFlow
JarvisFlow Sep. 8 at 4:26 PM
Jones Trading updates rating for CG Oncology ( $CGON ) to Buy, target set at 50.
0 · Reply
JarvisFlow
JarvisFlow Sep. 8 at 12:00 PM
HC Wainwright & Co. updates rating for CG Oncology ( $CGON ) to Buy, target set at 75.
0 · Reply
RiskCPremium
RiskCPremium Sep. 5 at 7:55 PM
$RLMD After the licensing agreement with Trigone for NDV-01 gel, stock price recovered a bit but still selling at an extremely deep Sergio Traversa/Key-Man/Conman discount. Just look at $CGON today, both are going after the same market but the NDV-01 gel shown much better efficacy so far. He burned and conned not only the shareholders but also analysts from reputable investment banks. That's why current stock price is $1.60 but analysts are keeping their average target price at $1.00. Dr. Raj Pruthi current CMO should lead the company. Trigone & Squadron Capital Management LLC should lead the Board.
1 · Reply
Grinding10
Grinding10 Sep. 5 at 3:22 PM
$CGON yeah ok there’s no insider trading I guess? $5 in 2 days when this hasn’t moved in 2 years
0 · Reply
MoneyWise13
MoneyWise13 Sep. 5 at 3:01 PM
$CGON This has BP buyout written all over it
1 · Reply
prismmarketview
prismmarketview Sep. 5 at 2:59 PM
(NASDAQ: $CGON) #cgoncology reports a 41.8% complete response rate at 24 months for cretostimogene in high-risk, BCG-unresponsive NMIBC. Impressively, 90% of 12-month responders remain disease-free at 24 months, with no serious treatment-related adverse events. https://prismmarketview.com/cg-oncologys-cretostimogene-sustains-durability-and-safety-12-new-patients-in-response-at-24-month/
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 4 at 10:00 PM
$CGON Excellent article that nails exactly where CGON stands right now. So if you want to update your CGON knowledge or get acquainted with CGON, this is a must read. https://beyondspx.com/quote/CGON/cg-oncology-unpacking-the-bladder-cancer-catalyst-cgon#analysis
0 · Reply
BullishBee
BullishBee Sep. 4 at 7:36 PM
🚀 Momentum Breakout Win: $CGON • Entry: $28.96 • Take Profit 1: $30.41 (+5.0%) • Final Exit: $31.60 (+9.1% Trail) • Return Locked: +7.1% (Total) Another premium breakout delivered with precision. Risk-free trade secured early, and the trailing stop locked in additional gains. The BullishBee momentum streak is alive and buzzing 🐝🔥
0 · Reply
dlhman2002
dlhman2002 Sep. 4 at 12:35 AM
$CGON Let the inflow begin...
0 · Reply
TitaniumTrades
TitaniumTrades Aug. 23 at 9:00 AM
$CGON CG Oncology Inc is a clinical stage immuno-oncology company with bladder cancer focus
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Aug. 22 at 12:52 AM
$IOVA Does anybody know or have an idea of the size of stock compensation component Corleen Roche, new IOVA CFO is set to receive? It is not yet submitted to sec. She had a lower salary at $CGON, a promising therapy for BCG-unresponsive NMIBC (planned for BLA filing later this year) but a significant equity component. Two questions pique my curiosity : 1) equity component in iova matches or far outweighs that of CGON or ; 2) she likes the approval chances of lung in IOVA vs that of CGON in nmibc ... cast your views. THX in advance
4 · Reply
TheTinMan
TheTinMan Aug. 20 at 5:44 PM
$TLTFF Lots of positive news coming up SOON. Ruvidar and Rutherin are miracle drugs. Latest data on NMIBC about to be released, potential HSV cure, listing on US exchange, trials on Glioblastoma, Lung and MIBC.. So much potential here. $CGON $IBRX $JNJ
0 · Reply
d_risk
d_risk Aug. 9 at 1:09 AM
$CGON - CG Oncology, Inc. - 10Q - Updated Risk Factors CGON warns that evolving healthcare reform could raise hurdles and costs for securing coverage and commercialization of cretostimogene and future products, potentially impacting pricing. #HealthcareReform #PharmaceuticalCommercialization #PricingPressure #RegulatoryRisk #Biotechnology 🟢 Added 🟠 Removed https://d-risk.ai/CGON/10-Q/2025-08-08
1 · Reply
monterocky848
monterocky848 Jul. 31 at 11:53 PM
$ANIP $CGON Hey win a lawsuit that guarantees no one is touching your revenue and fucking down; Why not
1 · Reply
OpenOutcrier
OpenOutcrier Jul. 30 at 11:46 AM
$CGON (+5.6% pre) CG Oncology wins Delaware jury trial against ANI Pharmaceuticals $ANIP https://ooc.bz/l/71754
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 29 at 6:00 PM
$CGON Really good write-up that perfectly summarizes CGON's present situation. So if you want to bring your CGON knowledge up to date or just discover CGON, this is required reading. https://beyondspx.com/article/cg-oncology-unpacking-the-bladder-cancer-catalyst-cgon
0 · Reply
pat_soons_shlong
pat_soons_shlong Jul. 24 at 6:02 AM
$CGON seriously thinking of entering a position here. I remember when this was an IPO Someone want to give me the numbers on the recent dilution and the reason for the April dump? Any timeline on FDA BLA approval? Or just 2H
2 · Reply
stonktrader99
stonktrader99 Jul. 22 at 7:54 PM
$CGON @monterocky848 Hold strong brother, gains otw.
0 · Reply
monterocky848
monterocky848 Jul. 22 at 4:58 PM
$CGON the only fucking biospec that establishes a lower base each milestone
0 · Reply
monterocky848
monterocky848 Jul. 22 at 4:50 PM
$CGON trash fucking stock; submit ur fucking BLA so I can exit please
0 · Reply